The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

amicas.com

Founded Year

1995

Stage

Acq - P2P | Acquired

Total Raised

$30.67M

Valuation

$0000 

Revenue

$0000 

About Amicas

AMICAS is engaged in radiology and medical image and information management solutions. The AMICAS ONE Suite aims to provide a complete, end-to-end solution for imaging centers, ambulatory care facilities, and radiology practices. Acute care and hospital clients are provided with a fully-integrated, HIS/RIS-independent PACS, featuring advanced enterprise workflow support and scalable design.

Amicas Headquarter Location

1210 Washington Street Suite 400

Newton, Massachusetts, 02460,

United States

617-244-1141

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Amicas News

Emageon acquired by Amicas, settles shareholder suit

Sep 27, 2019

Amicas, a provider of radiology and medical image and information management solutions, has completed its acquisition of Emageon—which settled a shareholder class action lawsuit in order to finalize the merger. In February, Amicas reported that one of its subsidiaries had commenced a tender offer to acquire all the outstanding shares of Emageon's common stock for approximately $39 million. As a result of the statutory merger completed Wednesday, Amicas now owns 100 percent of Birmingham, Ala.-based Emageon. Amicas had previously purchased 88 percent of  Emageon common stock pursuant to the tender offer, which expired on April 1. Pursuant to the merger, Emageon shareholders who did not tender their shares (other than those shareholders who properly exercise their dissenters' rights), will receive the same $1.82 per share in cash, without interest and less any required withholding taxes, that was paid to shareholders in the tender offer. On March 27, Emageon said that it and the other named defendants in a putative class action lawsuit filed by its shareholders on March 13, in connection with the proposed acquisition of Emageon by Amicas, have entered into a memorandum of understanding with counsel for the plaintiff. Under the terms of the memorandum, the parties have agreed to settle the lawsuit, subject to court approval, at which time the lawsuit will be dismissed with prejudice. Emageon and the other defendants maintain that the lawsuit is "completely without merit." Nevertheless, to avoid costly litigation and eliminate the risk of any delay to the closing of the tender offer and subsequent merger, the defendants have agreed to the settlement contemplated in the memorandum, according to Emageon. The Boston-based Amicas said that the combined solution suite will include radiology PACS, cardiology PACS, RIS, cardiology information systems, revenue cycle management systems, referring physician tools, business intelligence tools and EMR-enabling enterprise content management capabilities. With the completion of the merger, Emageon has become a wholly owned subsidiary of Amicas, and Emageon shares will cease to be traded on the Nasdaq Global Market. Subscribe to Health Imaging News The free newsletter covering the top medical imaging headlines Email

  • When was Amicas founded?

    Amicas was founded in 1995.

  • Where is Amicas's headquarters?

    Amicas's headquarters is located at 1210 Washington Street, Newton.

  • What is Amicas's latest funding round?

    Amicas's latest funding round is Acq - P2P.

  • How much did Amicas raise?

    Amicas raised a total of $30.67M.

  • Who are the investors of Amicas?

    Investors of Amicas include Merge Healthcare, VitalWorks, One Equity Partners, Beringea, Radius Ventures and 6 more.

  • Who are Amicas's competitors?

    Competitors of Amicas include Abaxis, Applied Spectral Imaging, Fenwal, Micronics Microfluidics, Inoveon and 11 more.

You May Also Like

O
OraMetrix

OraMetrix is a provider of 3-D technology solutions improving the quality and efficiency of orthodontic care. Its proprietary technology, the suresmile system, allows the use of precision digital tools throughout all phases of the orthodontic treatment process – diagnosis, treatment planning and monitoring, and archwire customization.

F
Forth Photonics

Forth Photonics is a medical device company that designs, develops, manufactures and markets imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. Forth Photonics aims to help medical practitioners to improve patient care by incorporating advanced biophotonics and optical molecular imaging technologies to assist in early detection, diagnosis and monitoring.

C
Cardiophotonics

Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration

V
Verax Biomedical

Verax Biomedical is the producer of the Platelet PGD Test, a test for bacterial contamination in platelets granted a Safety Measure claim by the FDA. The test can be used to extend the dating of apheresis platelets in plasma, the most common platelet type transfused in the U.S., from 5 to 7 days. This dating extension offers the opportunity for significant cost savings to the blood banking community while preserving a critical life giving resource.

K
Kjaya

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

I
Imorphics Limited

Imorphics is a spin-out from the Division of Imaging Science and Biomedical Engineering in the Faculty of Medicine and is based on more than 20 year's research led by Professor Chris Taylor. The company sells 3D medical image analysis software which is being used to improve the speed and accuracy of measurements taken in drug trials. MTF introduced Chairman Mike Bowes to the company. Mike Bowes was previously CEO of Kestra, an imaging start-up backed by 3i which was sold in 1999.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.